A trial natriuretic peptide (ANP) is the first described peptide in a family of hormones known to have important roles in the regulation of body fluid homeostasis.' It is secreted by atrial myocytes in response to increased intravascular volume. Once it is in the circulation, its effects are primarily on the kidney, vascular tissue, and adrenal gland, in which its actions lead to natriuresis, diuresis, and a decrease in intravascular volume and blood pressure.2 The description of the potent diuretic and natriuretic properties of atrial extracts more than a decade ago was the first evidence that the heart could be an endocrine organ.3 The subsequent isolation and characterization of this activity identified ANP as the first secreted cardiac hormone.4-7 ANP's actions on both the cardiovascular system and the kidney as well as its role in pathophysiological states such as heart failure, hypertension, and renal disease have made it a molecule of great interest to both clinical and basic scientists.1 The recent discovery of a family of structurally related hormones suggests that the physiological control of body fluid homeostasis is complex. This complexity is enhanced by the existence of at least three types of receptors specific for the natriuretic peptides. The aim of this review is to summarize the recent studies on the molecular biology of the natriuretic peptides and their receptors. Natriuretic Peptides After deBold et al's3 initial description of natriuretic activity in rat atrial extracts, several groups isolated rat ANPs of various lengths but with common amino acid sequences.4-8 Studies of the gene and messenger RNA (mRNA) encoding ANP demonstrated that the isolated peptides were various fragments of the naturally occurring hormone.9-12 ANP is synthesized first as the 152-amino-acid prepro-ANP (Figure 1) . Removal of the 24-amino-acid signal sequence (and the two carboxyl (C)-terminal arginine residues found in the rat, rabbit, and bovine but not human sequences) yields pro-ANP (1-126), the principal form of ANP stored in atrial granules.13 The bioactive peptide is generated by proteolytic cleavage of pro-ANP into predominantly ANP (99-126) and the inactive ANP (1-99).14 The active form of ANP (99-126) has a disulfide bridge between cysteines 105 and 121, and all ANP analogues with natriuretic or diuretic activity share this common central ring structure.815 Although pro-ANP is processed primarily to a 28-amino-acid hormone, as indicated in Figure 1 , other forms of ANP have been identified. Urodilatin, first isolated from human urine and synthesized in the kidney,'6 represents atypical processing to an amino (N)-terminally extended peptide, ANP (95-126).17 Alternatively processed forms of ANP have also been found in the testis (ANP )'1 and the brain (ANP and ANP ).'9
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trial natriuretic peptide (ANP) is the first described peptide in a family of hormones known to have important roles in the regulation of body fluid homeostasis.' It is secreted by atrial myocytes in response to increased intravascular volume. Once it is in the circulation, its effects are primarily on the kidney, vascular tissue, and adrenal gland, in which its actions lead to natriuresis, diuresis, and a decrease in intravascular volume and blood pressure. 2 The description of the potent diuretic and natriuretic properties of atrial extracts more than a decade ago was the first evidence that the heart could be an endocrine organ. 3 The subsequent isolation and characterization of this activity identified ANP as the first secreted cardiac hormone.4-7 ANP's actions on both the cardiovascular system and the kidney as well as its role in pathophysiological states such as heart failure, hypertension, and renal disease have made it a molecule of great interest to both clinical and basic scientists. 1 The recent discovery of a family of structurally related hormones suggests that the physiological control of body fluid homeostasis is complex. This complexity is enhanced by the existence of at least three types of receptors specific for the natriuretic peptides. The aim of this review is to summarize the recent studies on the molecular biology of the natriuretic peptides and their receptors. Natriuretic Peptides After deBold et al's3 initial description of natriuretic activity in rat atrial extracts, several groups isolated rat ANPs of various lengths but with common amino acid sequences.4-8 Studies of the gene and messenger RNA (mRNA) encoding ANP demonstrated that the isolated peptides were various fragments of the naturally occurring hormone.9-12 ANP is synthesized first as the 152-amino-acid prepro-ANP ( Figure 1) . Removal of the 24-amino-acid signal sequence (and the two carboxyl (C)-terminal arginine residues found in the rat, rabbit, and bovine but not human sequences) yields pro-ANP , the principal form of ANP stored in atrial granules. 13 The bioactive peptide is generated by proteolytic cleavage of pro-ANP into predominantly ANP (99-126) and the inactive ANP (Figure 2 ), 11 of these amino acids are identical in ANP, BNP, and CNP, whereas the N-and C-terminal tails vary in both length and composition.22-24 CNP has no C-terminal tail, and studies of the structure of the gene for CNP demonstrated that translation is terminated by a stop codon immediately after the final cysteine codon in the mRNA. [24] [25] [26] Among species, the amino acid sequence of both ANP and CNP are highly conserved, whereas the structure of BNP varies greatly ( Figure 3 ). For example, the mature 28-amino-acid human and porcine ANPs are identical, and there is only one substitution in the rat peptide.10"11,27,2, Studies of the complementary DNA (cDNA) precursors for CNP indicate that the 22-aminoacid forms of porcine, rat, and human CNP are identical.24-26The N-terminally extended 53-amino-acid form of CNP is identical in porcine and rat CNP and has only two substitutions in human CNP. In nonmammalian tissue, a 22-amino-acid form of chicken CNP is identical to the mammalian form except for three amino acid substitutions. 29 Within the heart, the atrium is the primary site of synthesis for both hormones. The ventricle produces ANP and BNP, but at levels 1,000-and 100-fold less than the atrium, respectively. This difference in peptide concentrations is also reflected at the RNA level in the rat.25 Northern blot analyses demonstrate a very high level of ANP mRNA in the atrium, and the difference in the levels of BNP mRNA in the atrium compared with the ventricle is much smaller than the difference in ANP mRNA concentrations in those regions. During cardiac disease, the expression of both ANP and BNP increases dramatically in both the atrium and ventricle.36 For BNP, the ventricle becomes the predominant site of hormone synthesis, and release into the anterior interventricular vein accounts for the increasing levels of circulating BNP. In patients with severe congestive heart failure, the plasma levels of both ANP and BNP are higher than control values; the increase in BNP concentrations, however, is at least 10 times greater than that of ANP. 36 These results suggest that ANP and BNP have distinct physiological and pathophysiological roles in cardiovascular control. Studies of infusions of BNP into patients with congestive heart failure support this hypothesis. Although the hemodynamic effects of BNP and ANP were similar in these patients, BNP had a longer duration of action and caused an enhanced rather than a blunted natriuretic response as was seen with ANP administration. 37 Both ANP and BNP immunoreactivity has been found in the central nervous system and the adrenal medulla as well as in cardiac tissue. 34 In the porcine brain, BNP levels are approximately 10-fold higher than those of ANP. Because the concentration of both of these peptides in the nervous system is much lower than in the heart or in the circulation, it has been postulated that the biological actions of ANP and BNP are predominantly in the periphery. The presence of these peptides in the brain, however, has led to many studies of the possible roles of ANP and, to a lesser extent, BNP in the central control of various cardiovascular functions.38 For example, injections of ANP or BNP into the rat brain cause changes in diuresis and salt appetite,39-45 heart rate and blood pressure,46,47 vasopressin secretion from the hypothalamus,48,49 and angiotensin lI-induced water intake.41,50-52 These results suggest that one important physiological role for natriuretic peptides in the brain is the regulation of the activity of the vasopressin and angiotensin II hypothalamic systems to maintain proper body fluid homeostasis. Therefore, even though the concentrations of ANP and BNP in the brain are much lower than those in the heart, these natriuretic peptides probably do have roles as neurotransmitters.
CNP appears to be localized exclusively to the central nervous system or to cells derived from the neural crest. Radioimmunoassay results indicate that CNP levels are 1.5-10 times higher than ANP and BNP in porcine brain (0.79 versus 0.06 and 0.52 pmol/g, respectively)34 and 30-70 times higher in human brain (1.04 versus 0.039 and 0.015 pmol/g, respectively).35 The significant levels of CNP-like immunoreactivity detected in both porcine and human heart (1-5 pmol/g) have been shown to be caused completely by cross-reactivity with the extremely high concentration of ANP. 35 and release it slowly. In fact, this receptor is quite abundant in vascular tissue, where it may serve to absorb excess ANP and protect against the sudden onset of dangerously low blood pressure. Recent evidence, however, has suggested that NPR-C may mediate the biological effects of ANP through second messengers other than cGMP. For example, analogues of ANP known to interact specifically with NPR-C have been shown to inhibit the production of cyclic AMP (cAMP) in various tissues70 and activate the phosphoinositol pathway in aortic smooth muscle cells.71 However, experiments measuring various signal transduction pathways in cells expressing the cloned human NPR-C have not yet been successful. 72 The three NPR subtypes each recognize the three known natriuretic peptides differentially. Doseresponse curves for stimulation of the guanylyl cyclase of NPR-A and NPR-B demonstrate that these receptors can be selectively activated ( Figure 5 ).73X74 Tissue culture cells transiently expressing the cloned human receptors were stimulated with various concentrations of the human hormones, and intracellular cGMP levels were determined. Both ANP and BNP can effectively stimulate NPR-A; BNP, however, is approximately 10-fold less potent. CNP, in contrast, does not significantly increase intracellular cGMP in cells expressing NPR-A. Because the NPR-A guanylyl cyclase is activated by both ANP and BNP, and both hormones have similar physiological effects in vitro20,54 and in vivo,76 it is possible that these two cardiac hormones exert their actions primarily through the same receptor, i.e., NPR-A. However, recent in vivo infusion experiments37 and studies of ANP and BNP levels36 in patients with congestive heart failure indicate that these two hormones have discrete physiological roles (see discussion above) and, therefore, may interact with distinct receptors. Perhaps there is an as yet unidentified member of the NPR guanylyl cyclase family that is specifically activated by BNP. Because the sequences of ANP and CNP are highly conserved across species, as are the sequences of their receptors, NPR-A and NPR-B,5558 respectively, it is possible that a BNP-specific receptor exists that displays as much structural diversity among species as does BNP itself.
Studies on the localization of the NPRs have been hampered by the lack of good antibodies for immunohistochemical studies. Receptor autoradiographic experiments using 'I-ANP to evaluate binding in various tissues77 have the drawback that this technique does not distinguish between the subtypes of NPRs, because both NPR-A and NPR-C bind ANP with high affinity. Recently, the differential expression of the mRNA for the three receptors has been examined in primate tissue Figure 7) . The (Figure 7) . When the KHD of NPR-A was replaced with the kinase domain of the EGF R (A[EGF R]A) or the KHD of the STa R (A[STa RJA), the resultant proteins were unable to correctly regulate the guanylyl cyclase activity. One possible explanation for these results is that although the identity between the kinaselike domains of NPR-A and NPR-B is 60%, these two NPRs are only 30% identical to either the STa R or the EGF R in the same region. These types of experiments indicate that the KHD is obviously an important regulator of the enzymatic activity of receptor guanylyl cyclases and may be the site of action for the effect of ATP, but understanding of the mechanism of this regulation awaits further study. Perhaps site-specific mutations within the kinaselike domain will help answer this question. Summary After the description in the past 5 years of BNP and CNP, interest in the natriuretic peptide family has dramatically increased. Molecular characterization of the receptors for this hormone family has identified a heterogeneity in the receptor subtypes not previously alluded to by pharmacological or biochemical studies. Much has been published on the physiology of ANP, but the major roles for BNP and CNP remain to be elucidated. Some experiments indicate that ANP and BNP may act synergistically, especially during cardiac stress36,37; however, the high level of structural diversity of BNP among species and the ability of porcine BNP, but not human BNP, to activate human NPR-B73 suggest that an as yet unidentified receptor may exist that specifically recognizes BNP. Localization studies have implied that CNP is the most prominent neuropeptide in the natriuretic peptide family, and the restriction of its receptor, NPR-B, to the nervous system suggests that CNP and NPR-B may act in the brain to coordinate the central aspects of body fluid homeostasis.
Of the three known NPRs, two, NPR-A and NPR-B, are capable of synthesizing their own second messenger, cGMP. The domain within these receptors that has high homology to protein kinases has been demonstrated to be essential for regulating this activity. No kinase activity has been measured in these proteins, but it is possible that this region is important for ATP regulation of guanylyl cyclase activity. This possibility raises interesting parallels with receptor-mediated cAMP signaling within cells. 
